The exit of private equity from their investments in contract research organizations (CROs) could threaten its growth, says two financial experts at Partnerships in Clinical Trials.
Breaking News
Subscribe to VCpost newsletter
Most Popular
- SSI Payment for May 2024: Supplemental Security Income Recipients to See Double Amount in Payout
- IBM Set to Acquire HashiCorp in Possible Mega-Deal, Stock Skyrockets 24% to $6.1 Billion Valuation
- Samsung to Implement Six-Day Work Week for Executives Slammed by Critics 'Not Effective'
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- Philippines Wants US, Japan to Fund Freight Railway Project After It Drops Funding Talks With China
- TikTok Ban in US Almost Inevitable After Senate Approves Bill Forcing Parent Company to Divest Owvnership or Face Prohibition
